FDA to Review Off-Label Marketing Regs

Sep 07, 2016

The FDA is announcing a 2-day public hearing to obtain input on issues related to the extent to which off-label information about treaments can be communicated to health care officials by drug manufacturers.

According to the agency, it is engaged in a comprehensive review of its regulations governing manufacturer's communications about unapproved uses of approved/cleared medical products, and the input from this meeting will inform FDA's policy development in this area.

While the FDA has traditionally taken tough stance on off-label marketing, drugmakers have argued that conveying certain types of information is protected by the First Amendment.

The hearing is scheduled for Nov. 9 and 10 at FDA offices in Silver Spring, Maryland.

Read the hearing notification

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments